TERAPIE SARS-COV-2 | Anticorpi Monoclonali

In rosso le review, in verde gli RCT.

• JAMA, editoriale 14 gennaio 2022 | “Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management”
• The Lancet, 23 dicembre 2021 | “Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial”
• The Lancet, 23 dicembre 2021 | “Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19”
• The Lancet Respiratory Medicine, 1 dicembre 2021 | “Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial”
• The Lancet Reumatology, 17 novembre 2021 | “Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial”
• New England Journal of Medicine , 27 ottobre 2021 | “Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab”
• New England Journal of Medicine, 7 ottobre 2021 | “Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19”
• New England Journal of Medicine, 29 settembre 2021 | “REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19”
• New England Journal of Medicine, 4 agosto 2021 | Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19”
• New England Journal of Medicine, 14 luglio 2021 | “Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19”
• Nature Medicine, 4 marzo 2021 | “Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies”
• AIFA, 5 febbraio 2021 | “Parere del CTS su anticorpi monoclonali”
• Science, 25 gennaio 2021 | “Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody”
• JAMA, 21 gennaio 2021 | “Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19A Randomized Clinical Trial”
• JAMA , 21 gennaio 2021 editoriale | “Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19”
• New England Journal of Medicine , 21 gennaio 2021 | “REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19”
• New England Journal of Medicine , 21 gennaio 2021 | “SARS-CoV-2 Neutralizing Antibody LY- CoV555 in Outpatients with Covid-19”
• New England Journal of Medicine, editoriale 21 gennaio 2021 | “Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection”
• New England Journal of Medicine, 17 dicembre 2020 | “REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19” 
•  JAMA, 11 dicembre 2020 | “An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19” 
• JAMA, 11 novembre 2020 | “The Challenges Ahead With Monoclonal Antibodies- From Authorization to Access”
•  New England Journal of Medicine, 28 ottobre 2020 | “SARS-CoV-2 Neutralizing Antibody LY- CoV555 in Outpatients with Covid-19”
•  New England Journal of Medicine, 21 ottobre 2020 | “Efficacy of Tocilizumab in Patients Hospitalized with Covid-19”
•  JAMA Internal Medicine, 20 ottobre 2020 | “Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia”
•  The Lancet, 2 ottobre 2020 | “Sarilumab use in severe SARS-CoV-2 pneumonia”
•  Nature, 11 agosto 2020 | “Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?”
•  AIFA, 17 giugno 2020 | “COVID-19: Studio randomizzato italiano, nessun beneficio dal tocilizumab”
•  Autoimmun Rev. 3 maggio 2020 | “Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy”
•  Clin Exp Rheumatol. 1 maggio 2020 | ” Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19”
•  AIFA, comunicato 13 maggio 2020 | “Studio Tocivid-19 – Risultati incoraggianti anche se non definitivi”